Roivant Sciences Ltd. (ROIV) News

Roivant Sciences Ltd. (ROIV): $10.40

0.44 (-4.06%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

B

Add ROIV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#59 of 363

in industry

Filter ROIV News Items

ROIV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ROIV News Highlights

  • For ROIV, its 30 day story count is now at 2.
  • Over the past 6 days, the trend for ROIV's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ROIV are DEC, IMVT and ROG.

Latest ROIV News From Around the Web

Below are the latest news stories about ROIVANT SCIENCES LTD that investors may wish to consider to help them evaluate ROIV as an investment opportunity.

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates. This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves

Yahoo | December 20, 2023

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to RVT-3101, a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Prior to the closing

Yahoo | December 14, 2023

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 studyIMVT-1402 600 mg was observed to deliver placebo-like impact on albumin and low-density lipoprotein cholesterol (LDL-C), similar to the previously disclosed 300 mg MAD cohort dataPotential best-in-class profile enables broad and exciting portfolio of indic

Yahoo | November 28, 2023

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) given the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this studyPriovant expects to announce topline results from the Phase 2 POC study of brepocitinib in non-infectious uveitis (NIU)

Yahoo | November 27, 2023

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitisIMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, based on initial results from Phase 1 single-ascending dose and 300 mg multiple-ascending dose studiesIMVT-1402 showed no statistically significant dose-rel

Yahoo | November 13, 2023

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. “I’m thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many

Yahoo | November 10, 2023

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in

Yahoo | October 30, 2023

This $5 Billion Biotech Home Run Took Less Than a Year

In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer.

Yahoo | October 24, 2023

FSR Stock Alert: What to Know as Fisker Drops Prices

Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV.

William White on InvestorPlace | October 23, 2023

PINS Stock Pops as Stifel Upgrades Pinterest

Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target.

William White on InvestorPlace | October 23, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!